394 related articles for article (PubMed ID: 27036386)
1. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity.
Wood R; Fermer S; Ramachandran S; Baumgartner S; Morlock R
J Rheumatol; 2016 Oct; 43(10):1897-1903. PubMed ID: 27036386
[TBL] [Abstract][Full Text] [Related]
2. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive dietary education in treated gout patients does not further improve serum urate.
Holland R; McGill NW
Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
5. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
6. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
[TBL] [Abstract][Full Text] [Related]
8. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
9. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.
Khanna PP; Perez-Ruiz F; Maranian P; Khanna D
Rheumatology (Oxford); 2011 Apr; 50(4):740-5. PubMed ID: 21147824
[TBL] [Abstract][Full Text] [Related]
11. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey.
Khanna PP; Nuki G; Bardin T; Tausche AK; Forsythe A; Goren A; Vietri J; Khanna D
Health Qual Life Outcomes; 2012 Sep; 10():117. PubMed ID: 22999027
[TBL] [Abstract][Full Text] [Related]
12. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
[TBL] [Abstract][Full Text] [Related]
13. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and disability in patients with treatment-failure gout.
Becker MA; Schumacher HR; Benjamin KL; Gorevic P; Greenwald M; Fessel J; Edwards L; Kawata AK; Frank L; Waltrip R; Maroli A; Huang B; ; Sundy JS
J Rheumatol; 2009 May; 36(5):1041-8. PubMed ID: 19332629
[TBL] [Abstract][Full Text] [Related]
15. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
16. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
18. Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study.
Uhlig T; Karoliussen LF; Sexton J; Provan SA; Kvien TK; Haavardsholm EA; Hammer HB
Rheumatology (Oxford); 2023 Dec; 62(12):3886-3892. PubMed ID: 36943375
[TBL] [Abstract][Full Text] [Related]
19. Serum urate goal attainment and associated factors in Chinese gout patients.
Guo G; Dong C; Yin R; Yang Y; Zhao R; Wang Y; Guo J; Zhou W; Lu G
Psychol Health Med; 2020 Sep; 25(8):931-939. PubMed ID: 31870173
[TBL] [Abstract][Full Text] [Related]
20. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
